FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1576142832> ?p ?o ?g. }

• W1576142832 abstract "Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CAMaternal embryonic leucine-zipper kinase (MELK), a member of the serine-threonine kinases snf1/AMP-activated protein family is involved in mammalian embryonic development. MELK is aberrantly upregulated in several types of solid cancer including glioblastoma and breast cancer, and implicated in formation and maintenance of cancer stem cells. Little is known about the relevance of this kinase in hematological malignancies. Our study aimed to explore the role of MELK in acute myeloid leukemia (AML) and identify whether targeting this kinase in leukemia stem cells may have therapeutic relevance. In order to characterize the expression of MELK in AML, we examined the protein levels in AML cell lines and primary blasts by western blot. MELK protein was expressed at variable levels in 10 out of 11 AML cell lines and primary blasts obtained from AML patients (n=5), representing diverse molecular and cytogenetic abnormalities of the disease. Importantly, we also found that MELK protein levels were higher in CD34+ cells compared with the more differentiated CD34- primary blasts from AML patient. To determine the role of MELK in AML, we utilized a loss of function approach in three AML cell lines (KG1, MV4-11 and U937 cells) and assessed cell viability by MTS. Cells transfected with MELK-siRNA showed significant decrease in cell viability (40-60%, P<0.05) compared with cells transfected with control-siRNA. In addition, knockdown of MELK expression resulted in increased apoptosis in MV4-11 and U937 cells assessed by AnnexinV staining.OTS167, a small molecule MELK kinase inhibitor is currently undergoing phase I clinical testing in patients with advanced solid malignancies. To examine the anti-leukemia activity of OTS167 in AML, we treated nine AML cell lines with this compound and assessed cells viability by MTS assay. Decrease in cell viability following treatment with increasing doses of OTS167 was time and dose dependent. Variable sensitivities among AML cell lines (IC50∼10-40nM at 48hrs) were observed. In addition, the compound promoted cell differentiation as assessed by CD11b staining in U937 cells. Treatment with (25 and 50nM) of OTS167 induced apoptosis by ∼30 and 40% in MV4-11 and MOLM13 cells at 48 hours post treatment (P=0.01 and 0.05, respectively). Similarly, OTS167 cytotoxicity (IC50 ∼ 10-40nM; n=3) and induced apoptosis was observed in primary AML blasts.In conclusion, MELK is expressed in AML cell lines and AML blasts with higher levels observed in less differentiated cells. MELK knockdown results in growth inhibition, apoptosis, and cell death suggesting that this kinase may act as a potential therapeutic target. MELK kinase inhibitor (OTS167) causes cytotoxicity in AML cell lines and primary blasts. These results warrant further preclinical evaluation of this compound as a novel targeted therapy for patients with AML.Citation Format: Houda Alachkar, Martin Mutonga, Suyoun Chung, Yo Matsuo, Wendy Stock, Yusuke Nakamura. Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 952. doi:10.1158/1538-7445.AM2014-952" @default.
• W1576142832 created "2016-06-24" @default.
• W1576142832 creator A5003617778 @default.
• W1576142832 creator A5005939966 @default.
• W1576142832 creator A5028493927 @default.
• W1576142832 creator A5057282547 @default.
• W1576142832 creator A5079171795 @default.
• W1576142832 creator A5082272702 @default.
• W1576142832 date "2014-09-30" @default.
• W1576142832 modified "2023-09-26" @default.
• W1576142832 title "Abstract 952: Preclinical efficacy of maternal embryonic leucine-zipper kinase (MELK) inhibition in acute myeloid leukemia" @default.
• W1576142832 doi "https://doi.org/10.1158/1538-7445.am2014-952" @default.
• W1576142832 hasPublicationYear "2014" @default.
• W1576142832 type Work @default.
• W1576142832 sameAs 1576142832 @default.
• W1576142832 citedByCount "1" @default.
• W1576142832 countsByYear W15761428322019 @default.
• W1576142832 crossrefType "proceedings-article" @default.
• W1576142832 hasAuthorship W1576142832A5003617778 @default.
• W1576142832 hasAuthorship W1576142832A5005939966 @default.
• W1576142832 hasAuthorship W1576142832A5028493927 @default.
• W1576142832 hasAuthorship W1576142832A5057282547 @default.
• W1576142832 hasAuthorship W1576142832A5079171795 @default.
• W1576142832 hasAuthorship W1576142832A5082272702 @default.
• W1576142832 hasConcept C10205521 @default.
• W1576142832 hasConcept C104317684 @default.
• W1576142832 hasConcept C145103041 @default.
• W1576142832 hasConcept C184235292 @default.
• W1576142832 hasConcept C203014093 @default.
• W1576142832 hasConcept C2778461978 @default.
• W1576142832 hasConcept C2778729363 @default.
• W1576142832 hasConcept C28328180 @default.
• W1576142832 hasConcept C502942594 @default.
• W1576142832 hasConcept C53227056 @default.
• W1576142832 hasConcept C54355233 @default.
• W1576142832 hasConcept C55493867 @default.
• W1576142832 hasConcept C81885089 @default.
• W1576142832 hasConcept C86803240 @default.
• W1576142832 hasConcept C95444343 @default.
• W1576142832 hasConceptScore W1576142832C10205521 @default.
• W1576142832 hasConceptScore W1576142832C104317684 @default.
• W1576142832 hasConceptScore W1576142832C145103041 @default.
• W1576142832 hasConceptScore W1576142832C184235292 @default.
• W1576142832 hasConceptScore W1576142832C203014093 @default.
• W1576142832 hasConceptScore W1576142832C2778461978 @default.
• W1576142832 hasConceptScore W1576142832C2778729363 @default.
• W1576142832 hasConceptScore W1576142832C28328180 @default.
• W1576142832 hasConceptScore W1576142832C502942594 @default.
• W1576142832 hasConceptScore W1576142832C53227056 @default.
• W1576142832 hasConceptScore W1576142832C54355233 @default.
• W1576142832 hasConceptScore W1576142832C55493867 @default.
• W1576142832 hasConceptScore W1576142832C81885089 @default.
• W1576142832 hasConceptScore W1576142832C86803240 @default.
• W1576142832 hasConceptScore W1576142832C95444343 @default.
• W1576142832 hasLocation W15761428321 @default.
• W1576142832 hasOpenAccess W1576142832 @default.
• W1576142832 hasPrimaryLocation W15761428321 @default.
• W1576142832 hasRelatedWork W1547256385 @default.
• W1576142832 hasRelatedWork W1980554214 @default.
• W1576142832 hasRelatedWork W2029329948 @default.
• W1576142832 hasRelatedWork W2047018224 @default.
• W1576142832 hasRelatedWork W2153263912 @default.
• W1576142832 hasRelatedWork W2163976460 @default.
• W1576142832 hasRelatedWork W2304558090 @default.
• W1576142832 hasRelatedWork W2313111831 @default.
• W1576142832 hasRelatedWork W2529977503 @default.
• W1576142832 hasRelatedWork W2531402480 @default.
• W1576142832 hasRelatedWork W2553016719 @default.
• W1576142832 hasRelatedWork W2579597326 @default.
• W1576142832 hasRelatedWork W2748639442 @default.
• W1576142832 hasRelatedWork W2784537211 @default.
• W1576142832 hasRelatedWork W2785207762 @default.
• W1576142832 hasRelatedWork W2807852229 @default.
• W1576142832 hasRelatedWork W2887715275 @default.
• W1576142832 hasRelatedWork W2979307109 @default.
• W1576142832 hasRelatedWork W2980275429 @default.
• W1576142832 hasRelatedWork W3201847257 @default.
• W1576142832 isParatext "false" @default.
• W1576142832 isRetracted "false" @default.
• W1576142832 magId "1576142832" @default.
• W1576142832 workType "article" @default.